These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
422 related articles for article (PubMed ID: 10681375)
21. Pharmacokinetics and metabolism of tesaglitazar, a novel dual-acting peroxisome proliferator-activated receptor alpha/gamma agonist, after a single oral and intravenous dose in humans. Ericsson H; Hamrén B; Bergstrand S; Elebring M; Fryklund L; Heijer M; Ohman KP Drug Metab Dispos; 2004 Sep; 32(9):923-9. PubMed ID: 15319332 [TBL] [Abstract][Full Text] [Related]
22. Identification of metabolites in urine and feces from rats dosed with the heterocyclic amine, 2-amino-3-methyl-9H-pyrido[2,3-b]indole (MeA alpha C). Frederiksen H; Frandsen H Drug Metab Dispos; 2004 Jun; 32(6):661-5. PubMed ID: 15155558 [TBL] [Abstract][Full Text] [Related]
23. The disposition and metabolism of [14C]fluconazole in humans. Brammer KW; Coakley AJ; Jezequel SG; Tarbit MH Drug Metab Dispos; 1991; 19(4):764-7. PubMed ID: 1680653 [TBL] [Abstract][Full Text] [Related]
24. Metabolism and excretion of the novel antipsychotic drug ziprasidone in rats after oral administration of a mixture of 14C- and 3H-labeled ziprasidone. Prakash C; Kamel A; Anderson W; Howard H Drug Metab Dispos; 1997 Feb; 25(2):206-18. PubMed ID: 9029052 [TBL] [Abstract][Full Text] [Related]
25. Disposition and metabolism of finasteride in dogs. Carlin JR; Christofalo P; Arison BH; Ellsworth RE; Rosegay A; Miller RR; Chiu SH; VandenHeuvel WJ Drug Metab Dispos; 1997 Jan; 25(1):100-9. PubMed ID: 9010636 [TBL] [Abstract][Full Text] [Related]
26. Metabolism, excretion, and pharmacokinetics of (3-{[4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-amino]-methyl}-phenoxy)-acetic acid, an EP2 receptor-selective prostaglandin E2 agonist, in male and female Sprague-Dawley rats. Johnson KA; Prakash C Drug Metab Dispos; 2005 Aug; 33(8):1191-201. PubMed ID: 15886349 [TBL] [Abstract][Full Text] [Related]
27. Metabolism and disposition of 14C-labeled peliglitazar in humans. Wang L; Munsick C; Chen S; Bonacorsi S; Cheng PT; Humphreys WG; Zhang D Drug Metab Dispos; 2011 Feb; 39(2):228-38. PubMed ID: 20978103 [TBL] [Abstract][Full Text] [Related]
28. Clinical pharmacokinetic of celecoxib in healthy Thai volunteers. Itthipanichpong C; Chompootaweep S; Wittayalertpanya S; Kemsri W; Thaworn N; Lilitkarntrakul P; Parikamsil S J Med Assoc Thai; 2005 May; 88(5):632-8. PubMed ID: 16149679 [TBL] [Abstract][Full Text] [Related]
29. Metabolism distribution and excretion of a matrix metalloproteinase-13 inhibitor, 4-[4-(4-fluorophenoxy)-benzenesulfonylamino]tetrahydropyran-4-carboxylic acid hydroxyamide (CP-544439), in rats and dogs: assessment of the metabolic profile of CP-544439 in plasma and urine of humans. Dalvie D; Cosker T; Boyden T; Zhou S; Schroeder C; Potchoiba MJ Drug Metab Dispos; 2008 Sep; 36(9):1869-83. PubMed ID: 18566038 [TBL] [Abstract][Full Text] [Related]
30. Metabolism, pharmacokinetics, and excretion of a cholesteryl ester transfer protein inhibitor, torcetrapib, in rats, monkeys, and mice: characterization of unusual and novel metabolites by high-resolution liquid chromatography-tandem mass spectrometry and 1H nuclear magnetic resonance. Prakash C; Chen W; Rossulek M; Johnson K; Zhang C; O'Connell T; Potchoiba M; Dalvie D Drug Metab Dispos; 2008 Oct; 36(10):2064-79. PubMed ID: 18653742 [TBL] [Abstract][Full Text] [Related]
31. Metabolism and excretion of ropivacaine in humans. Halldin MM; Bredberg E; Angelin B; Arvidsson T; Askemark Y; Elofsson S; Widman M Drug Metab Dispos; 1996 Sep; 24(9):962-8. PubMed ID: 8886605 [TBL] [Abstract][Full Text] [Related]
32. Absorption, metabolism, and excretion of [14C]vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in humans. He H; Tran P; Yin H; Smith H; Batard Y; Wang L; Einolf H; Gu H; Mangold JB; Fischer V; Howard D Drug Metab Dispos; 2009 Mar; 37(3):536-44. PubMed ID: 19074975 [TBL] [Abstract][Full Text] [Related]
33. Disposition of [1'-(14)C]stavudine after oral administration to humans. Zhou L; Kaul S; Liu-Kreyche P; Tran SB; Espina RR; Warrack BM; Roongta VA; Iyer RA Drug Metab Dispos; 2010 Apr; 38(4):655-66. PubMed ID: 20053818 [TBL] [Abstract][Full Text] [Related]
34. Absorption, metabolism, and excretion of [(14)C]MK-0524, a prostaglandin D(2) receptor antagonist, in humans. Karanam B; Madeira M; Bradley S; Wenning L; Desai R; Soli E; Schenk D; Jones A; Dean B; Doss G; Garrett G; Crumley T; Nirula A; Lai E Drug Metab Dispos; 2007 Jul; 35(7):1196-202. PubMed ID: 17431030 [TBL] [Abstract][Full Text] [Related]
35. Metabolism, pharmacokinetics, and excretion of the 5-hydroxytryptamine1b receptor antagonist elzasonan in humans. Kamel A; Obach RS; Colizza K; Wang W; O'Connell TN; Coelho RV; Kelley RM; Schildknegt K Drug Metab Dispos; 2010 Nov; 38(11):1984-99. PubMed ID: 20668248 [TBL] [Abstract][Full Text] [Related]
36. Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans. Weinz C; Schwarz T; Kubitza D; Mueck W; Lang D Drug Metab Dispos; 2009 May; 37(5):1056-64. PubMed ID: 19196845 [TBL] [Abstract][Full Text] [Related]
37. Disposition and pharmacokinetics of [14C]finasteride after oral administration in humans. Carlin JR; Höglund P; Eriksson LO; Christofalo P; Gregoire SL; Taylor AM; Andersson KE Drug Metab Dispos; 1992; 20(2):148-55. PubMed ID: 1352203 [TBL] [Abstract][Full Text] [Related]
38. Metabolism and disposition of imatinib mesylate in healthy volunteers. Gschwind HP; Pfaar U; Waldmeier F; Zollinger M; Sayer C; Zbinden P; Hayes M; Pokorny R; Seiberling M; Ben-Am M; Peng B; Gross G Drug Metab Dispos; 2005 Oct; 33(10):1503-12. PubMed ID: 16006570 [TBL] [Abstract][Full Text] [Related]
39. Absorption, metabolism and excretion of [(14)C]mirabegron (YM178), a potent and selective β(3)-adrenoceptor agonist, after oral administration to healthy male volunteers. Takusagawa S; van Lier JJ; Suzuki K; Nagata M; Meijer J; Krauwinkel W; Schaddelee M; Sekiguchi M; Miyashita A; Iwatsubo T; van Gelderen M; Usui T Drug Metab Dispos; 2012 Apr; 40(4):815-24. PubMed ID: 22269146 [TBL] [Abstract][Full Text] [Related]
40. A phase I, open-label, mass balance study of [(14)C] dacomitinib (PF-00299804) in healthy male volunteers. Bello CL; Smith E; Ruiz-Garcia A; Ni G; Alvey C; Loi CM Cancer Chemother Pharmacol; 2013 Aug; 72(2):379-85. PubMed ID: 23760812 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]